Chiusura precedente | 0,2800 |
Aperto | 2,9857 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 2,9857 - 2,9857 |
Intervallo di 52 settimane | 1,9750 - 6,8000 |
Volume | |
Media Volume | 1.757 |
Capitalizzazione | 1,651M |
Beta (5 anni mensile) | 0,73 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,2150 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
NEWS RELEASE – INSIDE AND REGULATED INFORMATION9 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary Q3-2023 Revenues IRVINE, CA, and HERSTAL, BELGIUM – October 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary third quarter 2023 revenues, units, and cash position. For the third quarter ended September 30, 2023, the Company expects to report revenues of approximately $19.3 million, representing an increase of 7
NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONOCTOBER 2, 2023, 4:00pm ET / 22:00 CET MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting IRVINE, CA, and HERSTAL, BELGIUM – October 2, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces a proposed transition from a dual listing of the Company's American Depos
NEWS RELEASE September 26, 2023, 5:00PM EDT / 23:00 CET Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM – September 26, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the University of Oxford to investigate the correlation